keyword
MENU ▼
Read by QxMD icon Read
search

rheumatologic emergencies

keyword
https://www.readbyqxmd.com/read/28282061/hydroxychloroquine-retinopathy
#1
REVIEW
I H Yusuf, S Sharma, R Luqmani, S M Downes
Hydroxychloroquine (HCQ; Plaquenil) is used increasingly in the management of a variety of autoimmune disorders, with well established roles in dermatology and rheumatology and emerging roles in oncology. Hydroxychloroquine has demonstrated a survival benefit in patients with systemic lupus erythematosus; some clinicians advocate its use in all such patients. However, Hydroxychloroquine and chloroquine (CQ) have been associated with irreversible visual loss due to retinal toxicity. Hydroxychloroquine retinal toxicity is far more common than previously considered; an overall prevalence of 7...
March 10, 2017: Eye
https://www.readbyqxmd.com/read/28255960/jak-stat-signaling-as-a-target-for-inflammatory-and-autoimmune-diseases-current-and-future-prospects
#2
REVIEW
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni, Daniella M Schwartz
The Janus kinase/signal transduction and activator of transcription (JAK-STAT) signaling pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Many cytokines involved in the pathogenesis of autoimmune and inflammatory diseases use JAKs and STATs to transduce intracellular signals. Mutations in JAK and STAT genes cause a number of immunodeficiency syndromes, and polymorphisms in these genes are associated with autoimmune diseases...
March 3, 2017: Drugs
https://www.readbyqxmd.com/read/28251009/idiopathic-pulmonary-hemosiderosis-in-a-child-with-recurrent-macrophage-activation-syndrome-secondary-to-systemic-juvenile-idiopathic-arthritis
#3
Kenan Barut, Sezgin Sahin, Amra Adrovic, Velat Sen, Ozgur Kasapcopur
Macrophage activation syndrome, a severe complication of systemic juvenile idiopathic arthritis and other inflammatory diseases, represents one of the most important rheumatological emergencies. Delayed diagnosis could lead to life-threatening complications. Pulmonary hemosiderosis has been classically characterized by a triad of anemia, hemoptysis, and lung infiltrates on chest radiogram. Although the majority of patients of pulmonary hemosiderosis are considered idiopathic, secondary hemosiderosis associated with known diseases could be seen...
2017: Case Reports in Pediatrics
https://www.readbyqxmd.com/read/28241879/time-to-diagnosis-in-juvenile-idiopathic-arthritis-a-french-perspective
#4
Laura Aoust, Linda Rossi-Semerano, Isabelle Koné-Paut, Perrine Dusser
BACKGROUND: Juvenile idiopathic arthritis (JIA) is a rare disease that is not widely known by paediatricians and general practitioner (GP) leading to diagnostic error and delayed care provision. We aimed to analyse patient's journey and time to diagnosis of JIA (delay from the first symptom to the diagnosis of JIA). We performed a retrospective cohort study of 67 patients diagnosed with JIA and seen in the paediatric rheumatology department of the Kremlin Bicêtre Hospital, between July 2002 and January 2015...
February 28, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28219691/hepatitis-b-reactivation-associated-with-immune-suppressive-and-biological-modifier-therapies-current-concepts-management-strategies-and-future-directions
#5
REVIEW
Rohit Loomba, T Jake Liang
Hepatitis B reactivation associated with immune suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus infection. The population at risk for HBV reactivation includes those who are either currently infected with HBV or have past exposure to HBV. Since curative and eradicative therapy for HBV is not currently available, there is a large reservoir of individuals at risk for HBV reactivation in the general population...
February 17, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28194545/to-stop-the-erosion-of-hope-the-dmard-category-and-the-place-of-semantics-in-modern-rheumatology
#6
Jonas Kure Buer
The category of disease-modifying anti-rheumatic drugs (DMARDs) emerged in the 1970s to describe drugs capable of altering the long-term destructive course of arthritis. It became a core concept in rheumatology's reorientation towards pharmaceuticals in the late twentieth century. By examining the earliest use of the term "disease-modifying" in scientific publications, this paper identifies the drugs that the category described when it first emerged. Leaning on systematic reviews of each of these drugs towards the end of their career in rheumatology, it then establishes that posterity would not recognize any of these early DMARDs as capable of altering the long-term course of the disease...
February 13, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28138340/the-experience-of-foot-problems-and-decisions-to-access-foot-care-in-patients-with-rheumatoid-arthritis-a-qualitative-study
#7
Oonagh Wilson, John Kirwan, Emma Dures, Enid Quest, Sarah Hewlett
BACKGROUND: Although foot problems are common in rheumatoid arthritis (RA), the consequences of foot problems from the patient perspective have not been fully explored. The aims of this study were to explore the experience of foot problems and decisions to access foot care services or not in patients with RA. METHODS: Semi structured, one-to-one interviews with patients recruited from 2 UK rheumatology units, purposively sampled for self-reported foot problems and a range of personal/disease characteristics...
2017: Journal of Foot and Ankle Research
https://www.readbyqxmd.com/read/28089200/limitations-of-the-current-standards-of-care-for-treating-gout-and-crystal-deposition-in-the-primary-care-setting-a-review
#8
Robert T Keenan
PURPOSE: This article outlines several important issues regarding the management of patients with gout. The topics discussed include best practices for gout based on the most current guidelines, opportunities for improving gout management, and current and emerging therapies for gout. METHODS: [PubMed and Google Scholar databases] were search for all articles and trials published before 2016, using the key terms [hyperuricemia, gout, tophi, joint erosion, joint damage, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), flare, comorbidity, epidemiology, adherence, serum uric acid (sUA), monosodium urate (MSU), <6 mg/dL, MSU crystal formation, as well as individual drug names and classes of treatments of interest (allopurinol, febuxostat, colchicine, non-steroidal anti-inflammatories (NSAIDs)]...
February 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28000011/public-health-awareness-of-autoimmune-diseases-after-the-death-of-a-celebrity
#9
Nicola Luigi Bragazzi, Abdulla Watad, Francesco Brigo, Mohammad Adawi, Howard Amital, Yehuda Shoenfeld
Autoimmune disorders impose a high burden, in terms of morbidity and mortality worldwide. Vasculitis is an autoimmune disorder that causes inflammation and destruction of blood vessels. Harold Allen Ramis, a famous American actor, director, writer, and comedian, died on the February 24, 2014, of complications of an autoimmune inflammatory vasculitis. To investigate the relation between interests and awareness of an autoimmune disease after a relevant event such as the death of a celebrity, we systematically mined Google Trends, Wikitrends, Google News, YouTube, and Twitter, in any language, from their inception until October 31, 2016...
December 20, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27993829/filgotinib-glpg0634-gs-6034-an-oral-jak1-selective-inhibitor-is-effective-in-combination-with-methotrexate-mtx-in-patients-with-active-rheumatoid-arthritis-and-insufficient-response-to-mtx-results-from-a-randomised-dose-finding-study-darwin-1
#10
R Westhovens, P C Taylor, R Alten, D Pavlova, F Enríquez-Sosa, M Mazur, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset, P Harrison
OBJECTIVES: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX. METHODS: In this 24-week phase IIb study, patients with moderate-to-severe active RA receiving a stable dose of MTX were randomised (1:1:1:1:1:1:1) to receive placebo or 50, 100 or 200 mg filgotinib, administered once daily or twice daily...
December 19, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27993828/filgotinib-glpg0634-gs-6034-an-oral-selective-jak1-inhibitor-is-effective-as-monotherapy-in-patients-with-active-rheumatoid-arthritis-results-from-a-randomised-dose-finding-study-darwin-2
#11
A Kavanaugh, J Kremer, L Ponce, R Cseuz, O V Reshetko, M Stanislavchuk, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset, P Harrison
OBJECTIVES: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX). METHODS: In this 24-week phase IIb study, patients with moderately to severely active RA were randomised (1:1:1:1) to receive 50, 100 or 200 mg filgotinib once daily, or placebo, after a ≥4-week washout from MTX. The primary end point was the percentage of patients achieving an American College of Rheumatology (ACR)20 response at week 12...
December 19, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27964737/evidence-based-decision-support-for-pediatric-rheumatology-reduces-diagnostic-errors
#12
COMPARATIVE STUDY
Michael M Segal, Balu Athreya, Mary Beth F Son, Irit Tirosh, Jonathan S Hausmann, Elizabeth Y N Ang, David Zurakowski, Lynn K Feldman, Robert P Sundel
BACKGROUND: The number of trained specialists world-wide is insufficient to serve all children with pediatric rheumatologic disorders, even in the countries with robust medical resources. We evaluated the potential of diagnostic decision support software (DDSS) to alleviate this shortage by assessing the ability of such software to improve the diagnostic accuracy of non-specialists. METHODS: Using vignettes of actual clinical cases, clinician testers generated a differential diagnosis before and after using diagnostic decision support software...
December 13, 2016: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/27863807/head-to-head-comparison-of-certolizumab-pegol-versus-adalimumab-in-rheumatoid-arthritis-2-year-efficacy-and-safety-results-from-the-randomised-exxelerate-study
#13
Josef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, Jeffrey R Curtis, Stephen Hall, Boulos Haraoui, Ronald van Vollenhoven, Christopher Cioffi, Cécile Ecoffet, Leon Gervitz, Lucian Ionescu, Luke Peterson, Roy Fleischmann
BACKGROUND: To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF inhibitors and to assess the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first TNF inhibitor at week 12...
December 3, 2016: Lancet
https://www.readbyqxmd.com/read/27860410/sarilumab-and-nonbiologic-disease-modifying-antirheumatic-drugs-in-patients-with-active-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-tumor-necrosis-factor-inhibitors
#14
Roy Fleischmann, Janet van Adelsberg, Yong Lin, Geraldo da Rocha Castelar-Pinheiro, Jan Brzezicki, Pawel Hrycaj, Neil M H Graham, Hubert van Hoogstraten, Deborah Bauer, Gerd R Burmester
OBJECTIVE: To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapy. METHODS: Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs...
February 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27843372/wissler-fanconi-syndrome-and-related-diagnoses-a-case-report
#15
Mustafa Q Albustani, Robert F Howard
INTRODUCTION: Wissler-Fanconi syndrome is a rare rheumatic syndrome that was first described during the 1940s in Europe. Since then, many papers have been written that cover all aspects of this syndrome, most of which are in French and German language, with only a very few in English (none of them recent). We report here a case that fulfils the criteria for Wissler-Fanconi syndrome. Under the more general descriptive umbrella of Wissler-Fanconi syndrome, our patient also fulfils the Modified Jones criteria, and the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for rheumatoid arthritis, and was interpreted by other internists and another rheumatologist as fulfilling the Yamaguchi criteria for adult onset Still's disease...
2016: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/27821272/targeting-cytokine-signaling-in-autoimmunity-back-to-the-future-and-beyond
#16
REVIEW
Kiyoshi Hirahara, Daniella Schwartz, Massimo Gadina, Yuka Kanno, John J O'Shea
Cytokines represent structurally diverse soluble factors with critical roles in normal immune function and the pathogenesis of autoimmunity. The emergence of many successful biological therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject. Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal. Thus, targeting the intracellular pathways employed by cytokines provides new therapeutic opportunities...
December 2016: Current Opinion in Immunology
https://www.readbyqxmd.com/read/27813423/emerging-drugs-and-therapeutics-for-systemic-sclerosis
#17
Jason J Lee, Janet E Pope
Treatment of systemic sclerosis (SSc) is challenging despite advances in medical therapeutics for other rheumatologic diseases. Significant disease modifying therapy is lacking for most patients with SSc, due to the heterogeneous multisystem nature of SSc and its complex pathophysiology. The emergence of organ based management strategies has provided guidance in patient care as well as research and drug development. Areas covered: Design and development of new compounds focused on the underlying fibrotic disease processes have been sparse...
December 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27803964/adrenal-crisis-while-on-high-dose-steroid-treatment-what-rheumatologist-should-consider
#18
REVIEW
Döndü Üsküdar Cansu, Güven Barış Cansu, Deniz Arik, Cengiz Korkmaz
Steroid treatment is commonly recommended for autoimmune disorders in rheumatology practice. While adrenal crisis may occur upon existence of an inducing factor in patients with known or unknown adrenal insufficiency as well as in those with a suppressed hypothalamic-pituitary-adrenal (HPA) axis due to chronic steroid use, addisonian crisis rarely develops in patients on supraphysiological doses of steroid and, when emerged, it might be very difficult to recognize. Here, we present a patient who developed adrenal crisis while receiving high-dose methylprednisolone treatment due to retroperitoneal fibrosis and we also discuss possible mechanisms with a brief literature review...
April 2017: Rheumatology International
https://www.readbyqxmd.com/read/27797750/social-media-use-among-young-rheumatologists-and-basic-scientists-results-of-an-international-survey-by-the-emerging-eular-network-emeunet
#19
Elena Nikiphorou, Paul Studenic, Christian Gytz Ammitzbøll, Mary Canavan, Meghna Jani, Caroline Ospelt, Francis Berenbaum
OBJECTIVES: To explore perceptions, barriers and patterns of social media (SM) use among rheumatology fellows and basic scientists. METHODS: An online survey was disseminated via Twitter, Facebook and by email to members of the Emerging European League Against Rheumatism Network. Questions focused on general demographics, frequency and types of SM use, reasons and barriers to SM use. RESULTS: Of 233 respondents (47 countries), 72% were aged 30-39 years, 66% female...
October 24, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27796482/-therapeutic-administration-of-immunoglobulins
#20
T Witte
BACKGROUND: Intravenously administered immunoglobulins have multiple modes of action that are anti-inflammatory. They can therefore be beneficial in a number of autoimmune disorders. OBJECTIVE: The aim of this article is to analyze and summarize studies on the administration of intravenous immunoglobulins in rheumatological diseases. METHODS: A selective search and analysis of the literature was carried out related to the mode of action and efficacy of intravenous immunoglobulins in rheumatological diseases...
December 2016: Zeitschrift Für Rheumatologie
keyword
keyword
97091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"